Premium
Epidemiology and persistence of rhinovirus in pediatric lung transplantation
Author(s) -
Ammerman Evan,
Sweet Stuart C.,
Storch Gregory A.,
Buller Richard S.,
Mason Sheila,
Conrad Carol,
Hayes Don,
Faro Albert,
Goldfarb Samuel B.,
Melicoff Ernestina,
Schecter Marc,
Visner Gary,
Heeger Peter S.,
Mohanakumar Thalachallour,
Williams Nikki,
DanzigerIsakov Lara
Publication year - 2020
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13422
Subject(s) - rhinovirus , medicine , lung transplantation , prospective cohort study , transplantation , population , bronchoalveolar lavage , lung , respiratory system , environmental health
Background Infection with rhinovirus (HRV) occurs following pediatric lung transplantation. Prospective studies documenting frequencies, persistence, and progression of HRV in this at‐risk population are lacking. Methods In the Clinical Trials in Organ Transplant in Children prospective observational study, we followed 61 lung transplant recipients for 2 years. We quantified molecular subtypes of HRV in serially collected nasopharyngeal (NP) and bronchoalveolar lavage (BAL) samples and correlated them with clinical characteristics. Results We identified 135 community‐acquired respiratory infections (CARV) from 397 BAL and 480 NP samples. We detected 93 HRV events in 42 (68.8%) patients, 22 of which (23.4%) were symptomatic. HRV events were contiguous with different genotypes identified in 23 cases, but symptoms were not preferentially associated with any particular species. Nine (9.7%) HRV events persisted over multiple successive samples for a median of 36 days (range 18‐408 days). Three persistent HRV were symptomatic. When we serially measured forced expiratory volume in one second (FEV1) in 23 subjects with events, we did not observe significant decreases in lung function over 12 months post‐HRV. Conclusion In conjunction with our previous reports, our prospectively collected data indicate that molecularly heterogeneous HRV infections occur commonly following pediatric lung transplantation, but these infections do not negatively impact clinical outcomes.